Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchNigella SativaNigella Sativa (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Loading...
More

Supplementary Data — Nigella Sativa for COVID-19: real-time meta analysis of 14 studies

@CovidAnalysis, May 2024, Version 23V23
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ HNS-COVID-PK Ashraf (RCT) 82% 0.18 [0.04-0.80] death 2/157 11/156 CT​1 Improvement, RR [CI] Treatment Control HNS-COVID-PK Ashraf (RCT) 67% 0.33 [0.01-7.99] death 0/107 1/103 CT​1 HNS-COVID-PK Ashraf (RCT) 79% 0.21 [0.05-0.92] death 2/50 10/53 CT​1 HNS-COVID-PK Ashraf (RCT) 84% 0.16 [0.11-0.24] no recov. 107 (n) 103 (n) CT​1 HNS-COVID-PK Ashraf (RCT) 75% 0.25 [0.15-0.41] no recov. 50 (n) 53 (n) CT​1 HNS-COVID-PK Ashraf (RCT) 82% 0.18 [0.12-0.27] viral+ 107 (n) 103 (n) CT​1 HNS-COVID-PK Ashraf (RCT) 77% 0.23 [0.14-0.38] viral+ 50 (n) 53 (n) CT​1 Al-Haidari (RCT) 96% 0.04 [0.00-0.70] death 0/160 14/259 Al-Haidari (RCT) 93% 0.07 [0.02-0.30] severe case 2/160 44/259 Aldwihi 24% 0.76 [0.54-1.03] hosp. 85/345 152/393 Koshak (RCT) 75% 0.25 [0.03-2.22] hosp. 1/91 4/92 Koshak (RCT) 43% 0.57 [0.42-0.78] no recov. 34/91 60/92 Bencheqr.. (DB RCT) 69% 0.31 [0.01-7.19] hosp. 0/29 1/23 Bencheqr.. (DB RCT) 9% 0.91 [0.48-1.72] no improv. 28 (n) 23 (n) Bencheqr.. (DB RCT) 35% 0.65 [0.29-1.43] no improv. 28 (n) 23 (n) Bencheqr.. (DB RCT) 43% 0.57 [0.22-1.43] viral+ 5/21 8/19 Said (RCT) 77% 0.23 [0.04-1.23] recovery 30 (n) 30 (n) Said (RCT) 89% 0.11 [0.02-0.58] recovery 30 (n) 30 (n) Said (RCT) 80% 0.20 [0.07-0.59] no recov. 30 (n) 30 (n) Said (RCT) 77% 0.23 [0.07-0.70] no recov. 30 (n) 30 (n) Said (RCT) 85% 0.15 [0.04-0.48] no recov. 30 (n) 30 (n) Said (RCT) 90% 0.10 [0.03-0.33] no recov. 30 (n) 30 (n) Said (RCT) 85% 0.15 [0.02-0.74] no recov. 30 (n) 30 (n) Said (RCT) 67% 0.33 [0.05-1.79] no recov. 30 (n) 30 (n) Said (RCT) 58% 0.42 [0.08-1.86] no recov. 30 (n) 30 (n) Said (RCT) 58% 0.42 [0.08-1.86] no recov. 30 (n) 30 (n) Said (RCT) 82% 0.18 [0.02-0.94] no recov. 30 (n) 30 (n) Said (RCT) 86% 0.14 [0.02-0.70] no recov. 30 (n) 30 (n) Said (RCT) 27% 0.73 [0.22-2.40] no recov. 30 (n) 30 (n) Said (RCT) 56% 0.44 [0.12-1.53] no recov. 30 (n) 30 (n) Said (RCT) 80% 0.20 [0.03-0.92] no recov. 30 (n) 30 (n) Said (RCT) 90% 0.10 [0.01-0.66] no recov. 30 (n) 30 (n) Said (RCT) 61% 0.39 [0.13-1.08] viral+ 30 (n) 30 (n) Said (RCT) 85% 0.15 [0.04-0.51] viral+ 30 (n) 30 (n) Said (RCT) 91% 0.09 [0.02-0.30] viral+ 30 (n) 30 (n) Said (RCT) 87% 0.13 [0.03-0.45] viral+ 30 (n) 30 (n) Idris 39% 0.61 [0.44-0.84] recov. time 26 (n) 25 (n) Idris 15% 0.85 [0.25-2.82] viral+ 3/13 6/22 Idris 40% 0.60 [0.39-0.91] viral+ 13/26 21/25 Karimi (RCT) 51% 0.49 [0.09-2.66] death 2/192 4/189 CT​1 Karimi (RCT) 61% 0.39 [0.08-2.00] ICU 2/192 5/189 CT​1 Karimi (RCT) 70% 0.30 [0.15-0.61] hosp. 184 (n) 174 (n) CT​1 Karimi (RCT) 67% 0.33 [0.17-0.65] no recov. 184 (n) 174 (n) CT​1 Karimi (RCT) 14% 0.86 [0.80-0.93] no recov. 184 (n) 174 (n) CT​1 Setayesh (RCT) -8% 1.08 [0.07-16.7] death 1/38 1/41 CT​1 Setayesh (RCT) 27% 0.73 [0.58-0.92] oxygen time 38 (n) 41 (n) CT​1 Setayesh (RCT) 29% 0.71 [0.63-0.81] hosp. time 38 (n) 41 (n) CT​1 Faruq (RCT) 6% 0.94 [0.63-1.38] death 29/75 31/75 ICU patients Faruq (RCT) 62% 0.38 [0.18-0.81] ventilation 8/75 21/75 ICU patients Faruq (RCT) 83% 0.17 [0.05-0.54] ventilation 3/75 18/75 ICU patients Faruq (RCT) 23% 0.77 [0.22-2.67] ICU 4/46 5/44 ICU patients Faruq (RCT) 28% 0.72 [0.34-1.53] ICU 9/46 12/44 ICU patients Faruq (RCT) 34% 0.66 [0.49-0.90] ICU 25/46 36/44 ICU patients Faruq (RCT) 7% 0.93 [0.83-1.05] ICU 41/46 42/44 ICU patients Al-Haidari 62% 0.38 [0.31-0.46] symp. case 68/188 180/188 Shehab 0% 1.00 [0.36-2.74] severe case 4/39 22/214 Chandra (RCT) 49% 0.51 [0.16-1.59] cases 4/52 8/53 CT​1 Chandra (RCT) 87% 0.13 [0.02-0.84] cases 1/51 8/53 CT​1 Chandra (RCT) 74% 0.26 [0.06-1.17] cases 2/51 8/53 CT​1 Daneshfard (RCT) 34% 0.66 [0.49-0.89] symp. case 37/89 53/84 CT​1 Daneshfard (RCT) 97% 0.03 [0.00-0.19] symp. case 1/89 35/84 CT​1 Daneshfard (RCT) 66% 0.34 [0.11-1.04] symp. case 4/89 11/84 CT​1 Daneshfard (RCT) 62% 0.38 [0.12-1.16] symp. case 4/89 10/84 CT​1 Daneshfard (RCT) 26% 0.74 [0.50-1.09] symp. case 29/89 37/84 CT​1 Daneshfard (RCT) -6% 1.06 [0.43-2.62] symp. case 9/89 8/84 CT​1 Daneshfard (RCT) 79% 0.21 [0.07-0.59] symp. case 4/89 18/84 CT​1 Daneshfard (RCT) 76% 0.24 [0.09-0.60] symp. case 5/89 20/84 CT​1 Daneshfard (RCT) 98% 0.02 [0.00-0.31] symp. case 0/89 25/84 CT​1 Nigella sativa COVID-19 outcomes c19early.org May 2024 1 CT: study uses combined treatment Favors nigella sativa Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit